- Third-party tested
- >99% purity
- 99%+ purity or full refund
- Same-day shipping
Retatrutide
Retatrutide (LY3437943) — Triple GLP-1 / GIP / glucagon receptor agonist
Verify this batch
- Same-day shipping before 12pm
- Free US shipping over $100
- 99%+ purity or full refund
- Secure checkout
Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist designed by Eli Lilly. The molecule simultaneously engages the GLP-1, GIP, and glucagon receptors — adding glucagon-receptor activation to the dual GLP-1/GIP profile of tirzepatide. A C20 fatty diacid is conjugated to enable non-covalent albumin binding and extend the half-life to roughly 6 days. In SURMOUNT and Phase 2 obesity trials, retatrutide produced the largest body-weight reductions reported to date for any peptide agent, making it one of the most closely watched molecules in current metabolic research.
Key research areas
Investigated for effects on glycemic control, insulin sensitivity, and resting energy expenditure in preclinical and clinical research.
Phase 2 trials reported up to 24.2% body-weight reduction at 48 weeks — the largest effect observed for any peptide agent to date.
Under active study for effects on hepatic steatosis, MASLD/MASH, and lipid profiles.
Research examines downstream effects on blood pressure, triglycerides, and waist circumference.
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.43
- Purity
- ≥99.0%
- PubChem ID
- 171390338
Metabolic regulation
Investigated for effects on glycemic control, insulin sensitivity, and resting energy expenditure in preclinical and clinical research.
Obesity
Phase 2 trials reported up to 24.2% body-weight reduction at 48 weeks — the largest effect observed for any peptide agent to date.
Hepatic outcomes
Under active study for effects on hepatic steatosis, MASLD/MASH, and lipid profiles.
Cardiometabolic risk
Research examines downstream effects on blood pressure, triglycerides, and waist circumference.
- Jastreboff AM et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514-526.
- Rosenstock J et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet, 402(10401), 529-544.
- Sanyal AJ et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30, 2037-2048.
Store lyophilized peptide at −20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days.
Specifications
- CAS
- 2381089-83-2
- Formula
- C221H342N46O68
- MW
- 4731.43
- Purity
- ≥99.0%
Our process
Lyophilization
Each peptide is freeze-dried under controlled vacuum conditions, ensuring long-term stability and consistent potency across every vial.
Verified purity
Every batch is tested by independent third-party labs using HPLC and mass spectrometry. Certificates of analysis are published for each product.
Same-day fulfillment
Orders placed before 12pm ship the same business day. We use insulated packaging and cold packs where required.
Frequently asked questions
Each vial contains lyophilized peptide powder at the labeled dosage. No solvents, fillers, or preservatives.
Every batch is HPLC-tested. Certificate of Analysis (COA) and HPLC report are available on the product page.
Store the lyophilized peptide at −20°C, dry and dark. See the Storage tab for product-specific details.
United States only, in temperature-controlled packaging. 3–5 day standard or 1–2 day express.
No. All products are for laboratory and research use only (RUO) and are not intended for human or veterinary use.